Successful Healthcare Companies: Prodia, Hermina Hospital, And Sido Appear On Forbes Asia's Best Under A Billion 2021 List

JAKARTA - A company engaged in the health industry, PT Prodia Widyahusada Tbk (PRDA) is one of the Indonesian companies that is included in the list of Forbes Asia's Best Under a Billion 2021.

For information, Forbes Asia's Best Under a Billion 2021 is a list containing the 200 best companies in Asia Pacific with income categories above 10 million US dollars and under 1 billion US dollars or Rp. 14 trillion.

Prodia's President Director Dewi Muliaty said that this achievement is the result of the hard work of all Prodia people as well as the support and trust of stakeholders.

"We continue to strive to record performance growth so that Prodia can always provide added value and optimal returns for our shareholders and stakeholders," he explained in response to the list of Forbes Asia's Best Under a Billion 2021, quoted from the information disclosure page of the Indonesia Stock Exchange (IDX). ), Tuesday September 14th.

Dewi said, Prodia is optimistic that the company's business can continue to grow sustainably and contribute to the health ecosystem in Indonesia. The criteria set by Forbes Asia in selecting companies in Asia Pacific for the list include growth in earnings per share (EPS) and return on equity (ROE), earnings, and non-financial performance such as corporate governance.

Forbes Asia selected the list from 20,000 companies in the Asia Pacific region. The company, which is included in the list of Forbes Asia's Best Under a Billion 2021, can be categorized as a middle-class company with long-term sustainability performance

There are 5 Indonesian companies that have made it into the Forbes Asia's Best Under a Billion 2021 list, namely PT Prodia Widyahusada Tbk, PT Mitra Keluarga Sejahtera Tbk, PT Medikaloka Hermina Tbk, PT Industri Jamu and Pharmacy Sido Muncul Tbk, and PT Mark Dynamics Indonesia Tbk.

In the first semester of 2021, Prodia managed to record a net revenue growth of 88.4 percent to IDR 1.2 trillion and a net profit of IDR 301.02 billion compared to the same period in the previous year.

The company has served more than 8 million health checks consisting of genomic tests, routine tests, COVID-19 tests, and other health checks in the first semester of 2021. Prodia's revenue contribution is dominated by more than 80 percent of non-COVID-19 tests, namely genomic tests. and routine tests.

This is in line with Prodia's commitment to promote the concept of health management (personalized medicine) so that one can predict disease risk based on the condition of their respective genes. The net profit margin and EBITDA margin increased to 24.3 percent and 35.9 percent, respectively.

The company managed to book a current ratio of 663.1 percent and a quick ratio of 638.4 percent. This financial ratio also reflects Prodia's balance sheet which is also getting stronger.

PRDA's total assets in the first semester of 2021 were recorded to have increased to Rp2.4 trillion compared to the previous year. Total equity increased to IDR 1.93 trillion compared to 2020 which reached IDR 1.78 trillion.

In terms of cash flow, PRDA managed to maintain net cash flow from operating activities in a surplus position in semester I/2021 to Rp378.20 billion, an increase of 188.98 percent compared to the same period in 2020.

Previously, in May 2021 Prodia won the Best Disclosure & Transparency award for the category of issuers with medium market capitalization at the 12th IICD Corporate Governance Awards organized by the Indonesian Institute for Corporate Directorship (IICD).

In August 2021, Prodia received third place in The Best CSR of the Year for the Public Company-Non Finance category at the Indonesia Corporate Social Responsibility Awards (ICSRA) 2021.